KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Sitagliptin, Metformin and Glimepiride Fixed-Dose Combination Compared to Co-Administration of Metformin and High-Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double-Blind, Double-Dummy, Phase 3 Clinical Study.

Rakesh Sahay, Ambanna Gowda, Manish Kumar Singh, A Gopal Rao, Ramesh Duraisamy, Dinesh Gangwani, Jitendra Shukla, Vikas Agarwal, Sandesh Sahebarao Patil, Ambrish C, Satish Babu K N, Arvind Palawat, Sandip Krishnrao Gofne, Abhay Kumar Sahoo, Pradeep Kumar Rai, Raisa Shaikh, Shruti Saha, Dipak Patil, Pravin Ghadge, Piyush Patel, Lalit Lakhwani, Suyog Mehta, Sadhna Joglekar

Diabetes Obes Metab 28(7) 6207-6216

PMID42070788
PMCIDPMC13243998
DOI10.1111/dom.70778
发表日期2026-05-03
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:ROC 图。
摘要

摘要

AIMS: This study assessed the efficacy and safety of a triple fixed-dose combination (FDC) of sitagliptin, metformin, and glimepiride versus co-administered metformin and glimepiride in Indian patients with uncontrolled Type 2 diabetes (T2D). MATERIALS AND METHODS: In this Phase 3, randomised, double-blind, double-dummy study, adult patients with T2D and glycated haemoglobin (HbA1c) of 8%-11%, despite treatment with metformin and glimepiride, were randomised 1:1 to triple FDC of sitagliptin 50 mg, metformin 1000 mg and glimepiride 1 mg (SITA + MET + GLIM group) or metformin 1000 mg and glimepiride 2 mg (Co-administration group) for 16 weeks. Patients assigned to the SITA + MET + GLIM group could continue treatment for a 12-week open-label period. The primary endpoint was the change in HbA1c from baseline to Week 16. RESULTS: Overall, 190 patients were randomised to the SITA + MET + GLIM group and 202 to the Co-administration group. The least squares mean (standard error) change from baseline in HbA1c at Week 16 was -1.79 (0.07%) in the SITA + MET + GLIM group and -1.27 (0.06%) in the co-administration group (estimated treatment difference -0.51; 95% confidence interval [CI] -0.69 to -0.33; p < 0.0001). The proportion of patients with HbA1c below 7% at Week 16 was 32.1% in the SITA + MET + GLIM group and 12.6% in the Co-administration group (p < 0.0001). Adverse events occurred in 25 patients (13.2%) in the SITA + MET + GLIM group and 30 patients (14.9%) in the Co-administration group. CONCLUSIONS: The triple FDC was superior to co-administered metformin and high-dose glimepiride for achieving glycaemic control and was well tolerated in Indian patients with T2D. TRIAL REGISTRATION: Clinical Trials Registry-India identifier: CTRI/2021/11/038169 (registered on 22 November 2021); URL: https://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjI1Mjk=&Enc=&userName=.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Trial profile. FDC, fixed‐dose combination.
非 KM Figure
FIGURE 2FIGURE 2 Glycaemic outcomes during the double‐blind treatment period (mITT population) (A) Mean glycated haemoglobin (HbA 1c ), change from baseline to Week 16. (B) Proportion of patients with HbA 1c below 7% at Week 12 and Week 16. n represents the number of patients in each treatment group. The double‐blind treatment period was from baseline to the end of Week 16. The mITT population included all enrolled patients who were administered at least one dose of study medication and returned for at least one post‐baseline evaluation visit. CI, confidence interval; HbA1c, glycated haemoglobin; mITT, modified intention‐to‐treat. *Triple fixed‐dose combination of sitagliptin phosphate 50 mg, metformin hydrochloride 1000 mg, and glimepiride 1 mg twice daily. †Co‐administration of metformin hydrochloride 500 mg (two tablets) and glimepiride 2 mg twice daily.
非 KM Figure